Welcome!

News Feed Item

ARTERIA Program - A $49.2M Investment for Patients With or at Risk of Cardiovascular Disease: the Montreal Heart Institute Will Pilot the #ARTERIA Research Program

MONTREAL, February 19, 2014 /PRNewswire/ --

The Montreal Heart Institute (MHI) announced last week the launch of ARTERIA, a research program aimed at developing ground-breaking treatments for cardiovascular diseases, the number one cause of death worldwide. "Once again, the Montreal Heart Institute and its team of dedicated physicians, researchers and professionals have established themselves as world leaders in the fight against heart disease. This program will have tangible positive effects on patients living with or at risk of developing cardiovascular disease," declared Dr. Jean-Claude Tardif, Director of the MHI Research Centre who will be leading the project.

The discoveries and innovations that will stem from this unique program will substantially benefit patients over the medium and long term by transforming medical practices in the treatment of heart disease, all while realizing major savings for the health system as a whole. Among its many benefits, ARTERIA will make it possible to deliver increasingly personalized medicine and to treat and medicate patients more effectively, thus saving lives. It is noteworthy that cardiovascular diseases are the leading cause of hospitalization and deaths in the world, and that 1.3 million Canadians suffer from various forms of the illness. Cardiovascular diseases also represent the largest economic burden of all diagnostic categories with total annual costs of approximately $22 billion in Canada.

Unprecedented partnership yields major investment of $49.2M

This monumental cutting-edge project has been made possible thanks to the $49.2 million it has received in funding. Of this amount, $31M has come from private investments linked to the biopharmaceutical sector and $18.2M has come from the Government of Quebec. "We are very proud at the Montreal Heart Institute Research Centre to have succeeded in attracting to this research program such key stakeholders as the Quebec Government, Université de Montréal, and the world's most innovative pharmaceutical companies, so that our patients may benefit from the fruits of this important research," added Dr. Tardif. ARTERIA will also lead to the creation of 150 new direct, high-skilled jobs.

The announcement was made in the presence of Quebec Premier, Pauline Marois, Ministers Nicolas Marceau, Jean-François Lisée and Élaine Zakaïb, Montreal Mayor, Denis Coderre, and representatives of international pharmaceutical companies. The program's main private partners attending the event were eager to praise the MHI Research Centre's initiative in establishing this innovative project. In doing so, they attested to the Institute's indisputable leadership on the world stage.

"Through our collaboration, we will be able to combine the MHI's worldwide network of scientific and medical research with our capabilities in translational medicine and clinical development. For this reason, to Hoffmann-La Roche Ltd, the Montreal Heart Institute is unequivocally a world-class Quebec institution," noted Ronnie Miller, President and Chief Executive Officer of Hoffmann-La Roche Ltd. Canada.

Frédéric Fasano, Canadian CEO of major ARTERIA partner Servier Canada Inc., for his part underscored the long-standing collaboration between the two organizations: "Our collaboration with the Montreal Heart Institute began over 15 years ago. It has been extremely productive in terms of research and innovation, case in point being a medication to treat patients with heart failure which was largely developed within the walls of the Institute. To work with the Montreal Heart Institute is to work alongside cardiologists and researchers of one of North America's top cardiology centres."

Lastly, major partner MedImmune (a subsidiary of AstraZeneca) stressed the uniqueness of the MHI and its model. "In taking part in the ARTERIA program, AstraZeneca, like all other public and private partners and all patients, will benefit from the internationally outstanding facility that is the Montreal Heart Institute. The Institute is the only one to offer an integrated model that runs the gamut from genetics, to cellular analysis, to major clinical studies. The Montreal Heart Institute is simply the only centre of its kind in the world," added Dr. Fouzia Laghrissi-Thode, Global Vice-President in charge of AstraZeneca's Cardiovascular and Metabolic division.

Dr. Guy Breton, Rector of the Université de Montréal, to which MHI is affiliated, was thrilled about the announcement. "We are very proud of the three Université de Montréal research teams that received funding as part of this new program. I especially congratulate Dr. Tardif and his team at the Montreal Heart Institute who are set to lead a research program that is innovative from every standpoint. On this Valentine's Day, which calls to mind the importance of the heart, I am delighted to know that researchers of such high calibre will have access to resources and partners that will enable them to develop new avenues to improve heart health."

The product of a vast and diversified partnership, ARTERIA has also been made possible by the significant contribution and tangible support of the following partners: Valeant Canada, Pharmascience Inc., Thrasos Therapeutics Inc., Pfizer Canada Inc., Spartan Bioscience Inc., and the Montreal Heart Institute Foundation.

To view the photo gallery: https://www.icm-mhi.org/en/pressroom/downloads-and-multimedia/photo-gallery

Founded by Dr. Paul David, The Montreal Health Institute is celebrating its 60th anniversary in 2014. This commemorative year will be the occasion to highlight the remarkable achievements in patient care, research, prevention and teaching that have led the MHI to rise to the ranks of the top cardiology centres in the world. Montreal-born and internationally renowned, the Montreal Heart Institute has for the past 60 years brought together impassioned experts who are devoted to pushing the boundaries of medicine in order to offer exceptional ultra-specialized care.

About the Montreal Heart Institute: http://www.icm-mhi.org.

facebook.com/institutcardiologiemontreal

@ICMtl

For further information:
Vanessa Lyssan
+1-514-266-5434
[email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Everywhere we turn in our industry we can find strong opinions about the direction, type and nature of cloud’s impact on computing and business. Another word that is used in every context in our industry is “hybrid.” In his session at 20th Cloud Expo, Alvaro Gonzalez, Director of Technical, Partner and Field Marketing at Peak 10, will use a combination of a few conceptual props and some research recently commissioned by Peak 10 to offer a real-world consideration of how the various categories of...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
SYS-CON Events announced today that Outscale, a global pure play Infrastructure as a Service provider and strategic partner of Dassault Systèmes, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2010, Outscale simplifies infrastructure complexities and boosts the business agility of its customers. Outscale delivers a secure, reliable and industrial strength solution for its customers, which in...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus intern...
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
In order to meet the rapidly changing demands of today’s customers, companies are continually forced to redefine their business strategies in order to meet these needs, stay relevant and continue to see profitable growth. IoT deployment and development is integral in this transformation, and today businesses are increasingly seeing the value of investing their resources into IoT deployments. These technologies are able increase ROI through projects such as connecting supply chains or enabling sm...
Regardless of what business you’re in, it’s increasingly a software-driven business. Consumers’ rising expectations for connected digital and physical experiences are driving what some are calling the "Customer Experience Challenge.” In his session at @DevOpsSummit at 20th Cloud Expo, Marco Morales, Director of Global Solutions at CollabNet, will discuss how organizations are increasingly adopting a discipline of Value Stream Mapping to ensure that the software they are producing is poised to o...
This talk centers around how to automate best practices in a multi-/hybrid-cloud world based on our work with customers like GE, Discovery Communications and Fannie Mae. Today’s enterprises are reaping the benefits of cloud computing, but also discovering many risks and challenges. In the age of DevOps and the decentralization of IT, it’s easy to over-provision resources, forget that instances are running, or unintentionally expose vulnerabilities.
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that EARP Integration will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. EARP Integration is a passionate software house. Since its inception in 2009 the company successfully delivers smart solutions for cities and factories that start their digital transformation. EARP provides bespoke solutions like, for example, advanced enterprise portals, business intelligence systems an...